about
Vaccine development for tuberculosis: current progressPrime-boost approaches to tuberculosis vaccine developmentPartially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.DNAVaxDB: the first web-based DNA vaccine database and its data analysis.Development of new tuberculosis vaccines: a global perspective on regulatory issuesRecombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.Infection with Helicobacter pylori is associated with protection against tuberculosis.Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial.Dual neonate vaccine platform against HIV-1 and M. tuberculosis.Systemic BCG immunization induces persistent lung mucosal multifunctional CD4 T(EM) cells which expand following virulent mycobacterial challengePulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.Identification of surrogates and correlates of protection in protective immunity against Mycobacterium bovis infection induced in neonatal calves by vaccination with M. bovis BCG Pasteur and M. bovis BCG Danish.Efficacy of a vaccine formula against tuberculosis in cattle.Comparative evaluation of booster efficacies of BCG, Ag85B, and Ag85B peptides based vaccines to boost BCG induced immunity in BALB/c mice: a pilot study.A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression.Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.Flow cytometric detection of gamma interferon can effectively discriminate Mycobacterium bovis BCG-vaccinated cattle from M. bovis-infected cattle.Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosisGoats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenDevelopment of vaccines against bovine tuberculosis.Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1Vaccine approaches to prevent tuberculosis.Single nucleotide polymorphisms that cause structural changes in the cyclic AMP receptor protein transcriptional regulator of the tuberculosis vaccine strain Mycobacterium bovis BCG alter global gene expression without attenuating growthConstruction of an Expression Vector Containing Mtb72F of Mycobacterium tuberculosis.Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice.Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectorsRecombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.Tuberculosis: vaccines in the pipeline.Recombinant vaccines and the development of new vaccine strategies.Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein.Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as tuberculosis vaccine.
P2860
Q26827737-B123A013-277A-4EAD-8DF4-A935A9A9B3ABQ27024526-B7CE7275-3BC2-42C2-904F-29121906AF7BQ28742762-85BE4166-1438-48C0-ABB7-4BE7957915A5Q30841376-FD57C6A2-CD18-4542-AEEC-C41701792D36Q33293376-EC404B07-7CFD-4702-B8E6-12609D367C6AQ33320536-54B01443-A78C-456B-86CA-088BBB814E38Q33466022-DD34ED1F-92EF-45C1-A306-A95BDB9F9985Q33526339-73964FED-04DC-489D-A033-ECCD1130CF81Q33656471-B809B585-3883-4614-8D57-9CE667E9348CQ33854478-10EB5616-9438-4974-9E7F-E4862673DC95Q33908584-90377E51-A48B-4D75-B041-F873DE9E585AQ33948002-70CC18FA-9B06-48DA-94F1-6D8BCF415639Q33954601-05AAE0FD-4AD6-49D4-A0CF-79BEDABBA3B2Q34146613-50D85B68-C8D7-45DF-9644-EABAC32939D7Q34739101-0109F193-844D-4C2D-A8BE-8834AFB48BA9Q35034673-8F1F5558-83C2-4E12-9099-FB4C702CAFD2Q35035635-DFFAFA3D-24CB-451A-A93C-F20380CD2740Q35054007-7FED6BFB-1BB6-4BBD-A823-C8617BE2F5E1Q35055665-8157C73E-4432-483B-A4BE-E82692ABEEEBQ35216135-E1F73A7D-8F03-41BC-9550-FFE7BA119023Q36094423-E3E4F7AB-69CC-4EA3-A388-9ADDCFDCA24CQ36143523-4B574D80-3FBA-48ED-BF87-A7C2176D97C0Q36191665-FA26568D-9BC8-4DEA-BCFA-64ECE4BA0017Q36315838-EBDE179B-A795-412C-8B0E-7DF7BA69FC8DQ36456190-B8E43A93-EE1C-47F6-897B-AD4C85DD139AQ36492602-F510DA2E-8A0D-4943-AA8F-C25FABD96827Q36539553-3E561A7D-62C2-4AAB-8CB3-DE24EEE6356FQ36570685-019462BB-2AAD-4473-A090-A5AFAE2B95BDQ36593916-1D70B7D5-50FD-4D8D-85D4-4FF04AB3762AQ36793706-3A3DC106-6B5B-47BD-9315-423CD0B563F4Q36898558-827B7801-0E96-407C-89F8-EAD22C2ABFD4Q36899073-24B63BC1-4996-4B57-8BE4-FD7A18B176DAQ36949611-17D703F2-E09F-4547-8C59-EF1F36D30FDFQ37114828-63D61753-6714-4FF1-8A84-28D010058C9BQ37167960-9ED2F355-2508-4091-8108-1189C18F456AQ37191912-63AFAAD6-7A15-4631-B3C0-4BA9E47DF5D4Q37194790-AA06673B-5A48-41AA-85DA-B0D06AFC4921Q37370940-3049DB36-9D53-4993-9F1D-88B1135B5CE6Q37461305-A095DB34-CB77-451C-9D6C-D64F574EFD5EQ37644063-AF91063E-DD88-49E6-98CD-470510D61FA7
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prime-boost immunisation strategies for tuberculosis.
@ast
Prime-boost immunisation strategies for tuberculosis.
@en
type
label
Prime-boost immunisation strategies for tuberculosis.
@ast
Prime-boost immunisation strategies for tuberculosis.
@en
prefLabel
Prime-boost immunisation strategies for tuberculosis.
@ast
Prime-boost immunisation strategies for tuberculosis.
@en
P1476
Prime-boost immunisation strategies for tuberculosis.
@en
P2093
Adrian Hill
P304
P356
10.1016/J.MICINF.2005.03.009
P577
2005-04-15T00:00:00Z